Abstract: A cooling member located in an upper part of a battery cell stack in which a plurality of battery cells are stacked includes an upper plate, a lower plate, and a coolant incorporated in an inner space between the upper plate and the lower plate. The lower plate includes a first part in which a fragile part is formed, and a second part in which the fragile part is not formed. A thickness value of the first part is smaller than a thickness value of the second part.

Abstract: An optical imaging system includes a first lens, a second lens, a third lens, and a fourth lens sequentially disposed from an object side toward an image side on an optical axis, and a reflecting member disposed closer to the object side, as compared to the first lens, and having a reflecting surface configured to change a path of light to be incident to the first to fourth lenses. The first to fourth lenses are disposed to be spaced apart from each other by a preset distance along the optical axis, and 1.3<TTL/BFL<3.5, where TTL is a distance from an object-side surface of the first lens to an imaging plane of an image sensor, and BFL is a distance from an image-side surface of the fourth lens to the imaging plane of the image sensor.

Abstract: The present disclosure relates to an isolated anti-FcRN antibody, which is an antibody binding to FcRN (stands for neonatal Fc receptor, also called FcRP, FcRB or Brambell receptor) that is a receptor with a high affinity for IgG or a fragment thereof, a method of preparing thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmunre diseases using the antibody. The FcRn-specific antibody according to the present disclosure binds to FcRn non-competitively with IgG to reduce serum pathogenic auto-antibody levels, and thus can be used for the treatment of autoimmune diseases.

Abstract: A system for treating atrial fibrillation includes a memory configured to store a baseline measurement of an atrial fibrillation characteristic of a patient and a post administration measurement of the atrial fibrillation characteristic of the patient. The post administration measurement is obtained subsequent to administration of a reactive oxygens species (ROS) scavenger to the patient. The system also includes a processor operatively coupled to the memory and configured to determine a change between the baseline measurement and the post administration measurement of the atrial fibrillation characteristic. The processor is further configured to identify, based on the determined change, one or more hot spots of atrial fibrillation, where the one or more hot spots comprise target areas for treatment of the atrial fibrillation.

Abstract: A memory device includes a plurality of latches arranged in a plurality of columns including a first column and a second column and in a plurality of rows, a first flip flop configured to output first data, to first latches arranged in the first column, among the plurality of latches, based on a clock, and a second flip flop configured to output second data, to second latches arranged in the second column, among the plurality of latches, based on the clock. The first flip flop is further configured to, in a lock time section in which the first latches and the second latches maintain an output regardless of an input, block output of the first data to the first latches, and the second flip flop is further configured to, in the lock time section, block output of the second data to the second latches.

Abstract: The preset invention relates to a high resolution mass spectrometry based novel bioinformatics platform for the identification of glycation proteins and advanced glycation end-product. Particularly, the bioinformatics platform of the present invention facilitates an efficient and accurate investigation of quantitative changes of glycation proteins and advanced glycation end-products which are included in various types of samples but had not been informed yet, and uses a high resolution mass spectrometry, and thereby can be effectively used for the prediction or diagnosis of a disease including cancer by examining a disease marker in a sample.

Abstract: The present invention relates to a bioinformation processing analysis method for the identification and quantification of O-linked glycopeptide using high resolution mass spectrum. Particularly, according to the bioinformation processing analysis method of the present invention, the quantitative changes of O-linked glycopeptide containing non-informed sugar chains included in various samples can be efficiently and accurately analyzed; the prediction or diagnosis of disease including cancer can be made easy by using a high resolution mass spectrometer; or the investigation of O-linked glycopeptide structure of a therapeutic glycoprotein can be efficiently achieved.

Abstract: A system for treating atrial fibrillation includes a memory configured to store a baseline measurement of an atrial fibrillation characteristic of a patient and a post administration measurement of the atrial fibrillation characteristic of the patient. The post administration measurement is obtained subsequent to administration of a reactive oxygens species (ROS) scavenger to the patient. The system also includes a processor operatively coupled to the memory and configured to determine a change between the baseline measurement and the post administration measurement of the atrial fibrillation characteristic. The processor is further configured to identify, based on the determined change, one or more hot spots of atrial fibrillation, where the one or more hot spots comprise target areas for treatment of the atrial fibrillation.

Abstract: A memory device includes a plurality of latches arranged in a plurality of columns including a first column and a second column and in a plurality of rows, a first flip flop configured to output first data, to first latches arranged in the first column, among the plurality of latches, based on a clock, and a second flip flop configured to output second data, to second latches arranged in the second column, among the plurality of latches, based on the clock. The first flip flop is further configured to, in a lock time section in which the first latches and the second latches maintain an output regardless of an input, block output of the first data to the first latches, and the second flip flop is further configured to, in the lock time section, block output of the second data to the second latches.

Abstract: The present invention relates to a bioinformation processing analysis method for the identification and quantification of O-linked glycopeptide using high resolution mass spectrum. Particularly, according to the bioinformation processing analysis method of the present invention, the quantitative changes of O-linked glycopeptide containing non-informed sugar chains included in various samples can be efficiently and accurately analyzed; the prediction or diagnosis of disease including cancer can be made easy by using a high resolution mass spectrometer; or the investigation of O-linked glycopeptide structure of a therapeutic glycoprotein can be efficiently achieved.

Abstract: A memory device includes a plurality of latches arranged in a plurality of columns including a first column and a second column and in a plurality of rows, a first flip flop configured to output first data, to first latches arranged in the first column, among the plurality of latches, based on a clock, and a second flip flop configured to output second data, to second latches arranged in the second column, among the plurality of latches, based on the clock. The first flip flop is further configured to, in a lock time section in which the first latches and the second latches maintain an output regardless of an input, block output of the first data to the first latches, and the second flip flop is further configured to, in the lock time section, block output of the second data to the second latches.

Abstract: The present invention relates to a diagnosis method of liver cancer using mass spectrometry of ?-fetoprotein derived glycopeptide. Particularly, according to the AFP glycopeptide analysis method of the invention, fucosylation rate of the glycopeptide having the sequence composed of Val-Asn-Phe-Thr-Glu-Ile-Gln-Lys is analyzed to diagnose liver cancer in the early developmental grade. In particular, fucosylation rate is higher in the liver cancer patients than in other liver disease patients, so that the comparison of the fucosylation rate can be useful to diagnose or distinguish liver cancer from other liver diseases in the early HCC patients.

Abstract: The present invention relates to a diagnosis method of liver cancer using mass spectrometry of ?-fetoprotein derived glycopeptide. Particularly, according to the AFP glycopeptide analysis method of the invention, fucosylation rate of the glycopeptide having the sequence composed of Val-Asn-Phe-Thr-Glu-Ile-Gln-Lys is analyzed to diagnose liver cancer in the early developmental grade. In particular, fucosylation rate is higher in the liver cancer patients than in other liver disease patients, so that the comparison of the fucosylation rate can be useful to diagnose or distinguish liver cancer from other liver diseases in the early HCC patients.

Abstract: A memory device includes a plurality of latches arranged in a plurality of columns including a first column and a second column and in a plurality of rows, a first flip flop configured to output first data, to first latches arranged in the first column, among the plurality of latches, based on a clock, and a second flip flop configured to output second data, to second latches arranged in the second column, among the plurality of latches, based on the clock. The first flip flop is further configured to, in a lock time section in which the first latches and the second latches maintain an output regardless of an input, block output of the first data to the first latches, and the second flip flop is further configured to, in the lock time section, block output of the second data to the second latches.

Abstract: The preset invention relates to a high resolution mass spectrometry based novel bioinformatics platform for the identification of glycation proteins and advanced glycation end-product. Particularly, the bioinformatics platform of the present invention facilitates an efficient and accurate investigation of quantitative changes of glycation proteins and advanced glycation end-products which are included in various types of samples but had not been informed yet, and uses a high resolution mass spectrometry, and thereby can be effectively used for the prediction or diagnosis of a disease including cancer by examining a disease marker in a sample.

Abstract: The present invention relates to a more efficient and accurate method for the identification and quantification of comparatively low abundant glycopeptides, compared with general peptides, using mass spectrum obtained by using high resolution mass spectrometer. Therefore, the method of the present invention can be effectively used for the techniques for identification of biotherapeutics and diagnosis of cancer or disease by screening glycopeptide, the disease marker (Biomarker), from various samples.

Abstract: A Fourier transform ion cyclotron resonance mass spectrometer (FT-ICR MS) includes: an ionization source generating ions; a deceleration lens, on which the ions generated by the ionization source and spatially dispersed are incident, selectively decelerating the incident ions so as to decrease the distance between the ions; and an ion cyclotron resonance cell on which the ions passing through the deceleration lens are incident. By preventing dispersing of ions due to mass difference and converging the ions using the deceleration lens, the mass range that can be measured at one time can be extended. Also, measurement sensitivity can be improved since the ions are effectively introduced to the ICR cell.

Abstract: The present invention relates to a more efficient and accurate method for the identification and quantification of comparatively low abundant glycopeptides, compared with general peptides, using mass spectrum obtained by using high resolution mass spectrometer. Therefore, the method of the present invention can be effectively used for the techniques for identification of biotherapeutics and diagnosis of cancer or disease by screening glycopeptide, the disease marker (Biomarker), from various samples.

Abstract: The present invention relates to a method for diagnosing cancer using information on the aberrant glycosylation of a glycoprotein involved in cancer progress. More particularly, the present invention relates to a cancer diagnosis peptide marker which is screened by the steps of: separating a glycoprotein aberrantly glycosylated according to the occurrence and progress of cancer from the blood of a lung cancer patient by using lectin; and selecting a marker peptide produced by the hydrolysis of the glycoprotein isolated by lectin. The marker peptide can be effectively used as a cancer diagnosis marker and for the diagnosis of cancer.

Abstract: The present invention relates to a peptide marker for cancer diagnosis and a cancer diagnosis method using the same, more precisely to a peptide marker for cancer diagnosis screened by the following steps: separating and concentrating glycoproteins including a certain glycan chain related to the occurrence of cancer; hydrolyzing the glycoproteins to obtain polypeptides; and quantitatively analyzing the polypeptides to identify certain polypeptides that can track quantitative changes in glycoproteins glycosylated in a specific manner by the occurrence of cancer, and to a cancer diagnosis method using the said peptide marker.